RPRX Stock Recent News

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share.

Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.

Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.

Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on track to exceed deployment targets.

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Chris Hite – Executive Vice President, Vice Chairman Terry Coyne – Executive Vice President, Chief Financial Officer Conference Call Participants Chris Shibutani – Goldman Sachs Hardik Parikh – J.P. Morgan Terence Flynn – Morgan Stanley Michael DiFiore – Evercore Michael Nedelcovych – TD Cowen Di Zhao – UBS Operator Ladies and gentlemen, thank you for standing by.